Welcome to our dedicated page for AINOS SEC filings (Ticker: AIMDW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ainos, Inc. filings document formal disclosures for a Texas public company whose securities include Nasdaq-listed warrants to purchase common stock under AIMDW. The record includes Form 8-K reports covering annual and quarterly results, AI Nose commercial announcements, strategic partnerships, at-the-market common stock offering activity and changes in the company’s independent registered public accounting firm.
Capital-structure disclosures include the completed reverse stock split of Ainos common stock and related adjustments to outstanding options and warrants. The filings also provide exhibits such as press releases, legal opinions, audit-firm correspondence and Inline XBRL cover-page data tied to the company’s reporting, financing, governance and material-event disclosures.
Taiwan Carbon Nano Technology Corporation (TCNT) updated its ownership and voting arrangements in Ainos, Inc. TCNT now beneficially owns 989,925 shares of Ainos common stock, representing 13.62% of the outstanding shares, after recent sales including 46,000 shares sold on January 28, 2026.
The filing explains that TCNT originally received Ainos shares in August 2024 under a license agreement, in exchange for granting an exclusive, irrevocable, and perpetual license to certain gas sensor and medical device patents. Ainos later implemented a one‑for‑five reverse stock split and TCNT has been gradually selling shares.
On January 1, 2026, TCNT entered into a voting agreement with Ainos Inc., a Cayman Islands corporation, covering the Ainos shares held by TCNT. Under this agreement, TCNT agreed to vote all of its Ainos voting stock as determined by Ainos KY in its sole discretion, effectively transferring voting control while retaining economic ownership.
Taiwan Carbon Nano Technology Corporation (TCNT) updated its ownership and voting arrangements in Ainos, Inc. TCNT now beneficially owns 989,925 shares of Ainos common stock, representing 13.62% of the outstanding shares, after recent sales including 46,000 shares sold on January 28, 2026.
The filing explains that TCNT originally received Ainos shares in August 2024 under a license agreement, in exchange for granting an exclusive, irrevocable, and perpetual license to certain gas sensor and medical device patents. Ainos later implemented a one‑for‑five reverse stock split and TCNT has been gradually selling shares.
On January 1, 2026, TCNT entered into a voting agreement with Ainos Inc., a Cayman Islands corporation, covering the Ainos shares held by TCNT. Under this agreement, TCNT agreed to vote all of its Ainos voting stock as determined by Ainos KY in its sole discretion, effectively transferring voting control while retaining economic ownership.
Taiwan Carbon Nano Technology Corp, a more than 10% owner of Ainos, Inc., reported selling 46,000 shares of Ainos common stock on January 28, 2026 at an average price of $2.1697 per share for general operating purposes.
After this transaction, the reporting shareholder directly owned 989,925 Ainos common shares.
Taiwan Carbon Nano Technology Corp, a more than 10% owner of Ainos, Inc., reported selling 46,000 shares of Ainos common stock on January 28, 2026 at an average price of $2.1697 per share for general operating purposes.
After this transaction, the reporting shareholder directly owned 989,925 Ainos common shares.
ScentAI Inc., a wholly owned subsidiary of Ainos, Inc., filed a Schedule 13D reporting beneficial ownership of 1,160,000 shares of Ainos common stock, representing 16.50% of the outstanding class. These shares have no voting power for so long as they are held by the wholly owned subsidiary.
ScentAI acquired the 1,160,000 Ainos shares on December 30, 2025 in exchange for 116,000,000 shares of ScentAI common stock. The filing states the stake was acquired for investment and general corporate purposes and notes that ScentAI currently has no specific plans for corporate actions involving Ainos, though it may review and change its intentions over time.
ScentAI Inc., a wholly owned subsidiary of Ainos, Inc., filed a Schedule 13D reporting beneficial ownership of 1,160,000 shares of Ainos common stock, representing 16.50% of the outstanding class. These shares have no voting power for so long as they are held by the wholly owned subsidiary.
ScentAI acquired the 1,160,000 Ainos shares on December 30, 2025 in exchange for 116,000,000 shares of ScentAI common stock. The filing states the stake was acquired for investment and general corporate purposes and notes that ScentAI currently has no specific plans for corporate actions involving Ainos, though it may review and change its intentions over time.
ScentAI Inc., a wholly owned subsidiary of Ainos, Inc., filed a Schedule 13D reporting beneficial ownership of 1,160,000 shares of Ainos common stock, representing 16.50% of the outstanding class. These shares have no voting power for so long as they are held by the wholly owned subsidiary.
ScentAI acquired the 1,160,000 Ainos shares on December 30, 2025 in exchange for 116,000,000 shares of ScentAI common stock. The filing states the stake was acquired for investment and general corporate purposes and notes that ScentAI currently has no specific plans for corporate actions involving Ainos, though it may review and change its intentions over time.
Ainos, Inc. filed an 8-K to report an update to its at-the-market stock offering program with H.C. Wainwright & Co., LLC as placement agent. The company previously established an agreement on May 31, 2024 to sell common stock with an aggregate offering price of up to $1,353,197, which was increased by a July 11, 2024 prospectus supplement to $1,840,350. Ainos has already sold common shares with an aggregate sales price of approximately $1,840,337 under this program. On September 5, 2025, Ainos filed a new prospectus supplement for an additional $874,496 of common stock under the same at-the-market agreement.
Ainos, Inc. is updating its at-the-market equity program to offer and sell up to $874,496 of common stock through H.C. Wainwright & Co. as sales agent. This supplements its existing Sales Agreement and reflects the updated capacity the company may use from time to time under its shelf registration. The filing notes that Ainos has already sold $1,840,337 of securities under the Sales Agreement and General Instruction I.B.6 of Form S-3 during the prior 12-month period. As of September 5, 2025, public float was about $8,144,499, based on 4,759,021 shares outstanding at a price of $4.11 per share, which constrains primary offerings to no more than one-third of that float in any 12-month period while float remains below $75 million.
Ainos, Inc. reported that it furnished its financial results for the quarter ended June 30, 2025 via a Current Report on Form 8-K dated August 13, 2025. The filing states a press release announcing those results is furnished as Exhibit 99.1 and that a Cover Page Interactive Data File is included as Exhibit 104. The report notes these materials are being furnished and are not deemed "filed" for purposes of Section 18 of the Exchange Act.
The 8-K identifies the company as a Texas corporation with principal offices in San Diego and lists its common stock (AIMD) and warrants (AIMDW) as Nasdaq-listed securities. The report is signed by Chun-Hsien Tsai, Chief Executive Officer. No financial amounts or results are included directly in the text of this Form 8-K.
Form 8-K – Item 8.01 Other Events
On 6-Aug-2025, Ainos, Inc. (Nasdaq: AIMD; AIMDW) reported that it has secured a US$2.1 million order from ASE Technology Holding Co., Ltd. to deploy the company’s AI Nose sensing platform in a semiconductor manufacturing environment. The related press release is provided as Exhibit 99.1.
The filing contains no revisions to previously issued financial statements, no earnings guidance, and no additional contractual terms beyond the order’s value and intended use. Other than standard cover information, Items 8.01 and 9.01 are the only sections with substantive disclosure.